This is directly addressed with immuno‐oncology drugs, but even drugs such as BTK inhibitors which have previously focused on B‐cell effects in WM can have broader ramifications and potential efficacy outside of the on‐target tumour activity [154]. Here, BTK is linked to neoplasm.